The value of specific serum in the treatment of pneumococcic pneumonia has been recognized for many years. Recently the effectiveness of sulfapyridine in this disease has become equally well established. The indications for the employment of each of these therapeutic agents, the methods of administration, the results to be expected from their use and the possible toxic effects are by now almost universally known. What is not known, however, is the relative value of the two agents when either is used alone or when they are administered in combination.
In table 1 are shown the results of treatment with serum alone as compared with those following treatment with sulfapyridine alone in several clinics where comparative studies have been made. Pneumococci of all types were represented among the causative agents in these cases. Volini, Levitt and Campione1 reported that 15, or 9.8 per cent, of 153 patients treated with specific
DOWLING HF, ABERNETHY TJ, HARTMAN CR. SHOULD SERUM BE USED IN ADDITION TO SULFAPYRIDINE: IN THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA? JAMA. 1940;115(25):2125–2128. doi:10.1001/jama.1940.02810510001001
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: